Skip to main navigation
  • Facebook
  • Twitter
  • Instagram
+1 (866) 450-4223 sales@drmtchdev.wpengine.com

Investor Relations

  • Products
    • PLA
      • For Physicians
      • For Patients
    • Carcinome
    • Inflammatory
  • About Us
    • Meet Our Team
    • Careers
    • Contact Us
  • Collaborations
  • News
  • Publications
  • Physician Resources
  • Patient Services
  • Investor Relations
    • Overview
    • News & Events
      • Press Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Quarterly Results
    • Analyst Coverage
    • Investor Resources
      • Investor FAQs
      • Contact IR
      • Email Alerts
DermTech

Press Releases

3

Investor Relations

  • Press Releases
  • Events
  • Presentations

Press Releases

Mar 14, 2023
DermTech to Present Four New Posters and Demonstrate its Smart Stickers™ at the 2023 American Academy of Dermatology (AAD) Annual Meeting
Mar 07, 2023
DermTech Adds Approximately 1.9 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
Mar 03, 2023
DermTech to Present at March Investor Conferences
Mar 02, 2023
DermTech Reports Fourth-Quarter and Full-Year 2022 Financial Results; Company Announces CEO Transition Plan
Feb 10, 2023
DermTech Announces Release Date for Fourth-Quarter 2022 Financial Results
Feb 09, 2023
DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by the Veterans Health Administration
Jan 27, 2023
DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 23, 2023
DermTech Adds Approximately 1.2 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
Jan 10, 2023
DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by TRICARE
Jan 05, 2023
DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)

Investor Tools

Print
Email Page
Email Alerts
RSS Feeds
Contact IR

Products

  • PLA for Physicians
  • PLA for Patients
  • Carcinome
  • Inflammatory Disease

About Us

  • Meet Our Team
  • Licensing
  • Collaborations
  • Investor Relations
  • Publications
  • Contact Us
  • Careers
  • Privacy Policy

News

  • Media Coverage
  • Press Releases
  • Physician Blog

Follow Us

Footer Column Last

Physician Portal

Find a Physician

Copyright © 2023 DermTech. All Rights Reserved.
We use cookies to improve your experience on the DermTech website. Accept Privacy Policy